Abstract
Purpose of review: To provide an update of the current state of antibody therapy for Severe Acute Respiratory Syndrome Coronavirus 2 infection that has progressed immensely in a very short time period.
Recent findings: Limited clinical effect of classical passive immunotherapy (plasma therapy, hyperimmune immunoglobulin [IgG] preparations) whereas monoclonal antibody therapy, if initiated early in the disease process, shows promising results.
Summary: Although antibody therapy still remains to be fully explored in patients with COVID-19, a combination of IgG monoclonal antibodies against the receptor-binding domain of the spike protein currently appears to provide the best form of antibody therapy, Immunoglobulin A dimers and Immunoglobulin M pentamers also show promising preliminary therapeutic results.
【초록키워드】 IgG, coronavirus, therapy, antibody, Antibody therapy, Immunotherapy, monoclonal antibody, Infection, severe acute respiratory syndrome Coronavirus, coronavirus 2, plasma therapy, monoclonal antibody therapy, Spike protein, Clinical effect, Severe acute respiratory syndrome, Receptor-binding domain, Immunoglobulin, therapeutic, plasma, respiratory, Combination, immunoglobulin M, best, recent, hyperimmune, classical, the disease, appear, the spike protein, the receptor-binding domain, initiated, Limited, patients with COVID-19, progressed, 【제목키워드】 COVID-19,